Devang Panchal

704 total citations
7 papers, 511 citations indexed

About

Devang Panchal is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Biotechnology. According to data from OpenAlex, Devang Panchal has authored 7 papers receiving a total of 511 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 2 papers in Biotechnology. Recurrent topics in Devang Panchal's work include Lung Cancer Treatments and Mutations (3 papers), Cancer Research and Treatments (2 papers) and Cancer Genomics and Diagnostics (2 papers). Devang Panchal is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), Cancer Research and Treatments (2 papers) and Cancer Genomics and Diagnostics (2 papers). Devang Panchal collaborates with scholars based in Canada, Australia and India. Devang Panchal's co-authors include Ming‐Sound Tsao, Melania Pintilie, Frances A. Shepherd, Christine To, Lisa Leung, Chang‐Qi Zhu, Nikolina Radulovich, Bizhan Bandarchi, Varune Rohan Ramnarine and Sandy Der and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Devang Panchal

6 papers receiving 503 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Devang Panchal Canada	5	303	235	190	108	64	7	511
Marco Petronio France	4	407 1.3×	166 0.7×	313 1.6×	113 1.0×	38 0.6×	5	567
Christine To Canada	9	323 1.1×	391 1.7×	196 1.0×	173 1.6×	32 0.5×	11	708
Daniel Brungs Australia	14	322 1.1×	180 0.8×	175 0.9×	151 1.4×	35 0.5×	47	565
Gregory C. Stachelek United States	7	191 0.6×	225 1.0×	142 0.7×	72 0.7×	28 0.4×	15	414
Georg Fluegen Germany	11	445 1.5×	272 1.2×	270 1.4×	128 1.2×	46 0.7×	35	733
Brian Datnow United States	8	254 0.8×	173 0.7×	168 0.9×	116 1.1×	21 0.3×	16	444
M Mueller Germany	7	586 1.9×	495 2.1×	161 0.8×	83 0.8×	40 0.6×	15	804
Brunella Costanza Belgium	8	197 0.7×	279 1.2×	156 0.8×	56 0.5×	18 0.3×	9	470
Gemma Domínguez Spain	6	357 1.2×	274 1.2×	137 0.7×	60 0.6×	38 0.6×	7	552
Brett H. Simmons United States	8	201 0.7×	257 1.1×	124 0.7×	151 1.4×	28 0.4×	9	488

Countries citing papers authored by Devang Panchal

Since Specialization

Citations

This map shows the geographic impact of Devang Panchal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Devang Panchal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Devang Panchal more than expected).

Fields of papers citing papers by Devang Panchal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Devang Panchal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Devang Panchal. The network helps show where Devang Panchal may publish in the future.

Co-authorship network of co-authors of Devang Panchal

This figure shows the co-authorship network connecting the top 25 collaborators of Devang Panchal. A scholar is included among the top collaborators of Devang Panchal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Devang Panchal. Devang Panchal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Martin, Petra, Erin Stewart, Nhu‐An Pham, et al.. (2016). Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model. Clinical Lung Cancer. 17(5). 375–383.e2. 11 indexed citations

Stewart, Erin, Céline Mascaux, Devang Panchal, et al.. (2014). Abstract 1184: Modeling mechanisms of resistance of epidermal growth factor receptor (EGFR) mutations to targeted drugs through patient-derived xenografts (PDX) of non-small cell lung cancer (NSCLC). Cancer Research. 74(19_Supplement). 1184–1184. 1 indexed citations

Leung, Lisa, Nikolina Radulovich, Chang‐Qi Zhu, et al.. (2012). Lipocalin2 Promotes Invasion, Tumorigenicity and Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. PLoS ONE. 7(10). e46677–e46677. 56 indexed citations

John, Thomas, Naoki Yanagawa, Derek M. Kohler, et al.. (2012). Characterization of Lymphomas Developing in Immunodeficient Mice Implanted With Primary Human Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 7(7). 1101–1108. 29 indexed citations

Navab, Roya, Dan Strumpf, Bizhan Bandarchi, et al.. (2011). Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proceedings of the National Academy of Sciences. 108(17). 7160–7165. 293 indexed citations

John, Thomas, Derek M. Kohler, Melania Pintilie, et al.. (2010). The Ability to Form Primary Tumor Xenografts Is Predictive of Increased Risk of Disease Recurrence in Early-Stage Non–Small Cell Lung Cancer. Clinical Cancer Research. 17(1). 134–141. 121 indexed citations

John, Thomas, Mingyuan Li, Devang Panchal, et al.. (2009). Correlation of primary tumor engraftment in immune deficient mice and relapse rate in patients with early-stage non-small cell lung carcinoma (NSCLC). Journal of Clinical Oncology. 27(15_suppl). 11082–11082.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact